Rapamycin prevents, but does not reverse, aberrant migration in Pten knockout neurons

Area of Science:

• Neuroscience
• Developmental Biology
• Genetics

Background:

• Phosphatase and tensin homolog (PTEN) is a key negative regulator of the Akt/mammalian target of rapamycin (MTOR) pathway.
• PTEN mutations are associated with autism, macrocephaly, and focal cortical dysplasia (FCD).
• The role of PTEN in neuronal migration remains largely uncharacterized.

Purpose of the Study:

• To investigate the role of PTEN in neuronal migration.
• To determine if the MTOR inhibitor rapamycin can prevent or reverse aberrant neuronal migration caused by PTEN loss.
• To elucidate the specific MTOR complex (mTORC1 vs. mTORC2) involved in PTEN-dependent migration.

Main Methods:

• Utilized a conditional Pten knockout mouse model with retroviral delivery of Cre recombinase to induce gene deletion in specific neuronal populations.
• Quantified the position of Pten knockout (KO) neurons in the dentate gyrus granule cell layer over time post-injection.
• Administered rapamycin either preventatively (before migration defects were established) or for reversal (after defects appeared) and assessed its effects on neuronal migration and cell size.

Main Results:

• Pten KO neurons exhibited aberrant migration beginning at 7.5 days post-injection.
• Rapamycin treatment prevented and reversed somal hypertrophy in Pten KO neurons.
• While rapamycin prevented aberrant migration, it could not reverse it once established.
• Aberrant migration was found to be mediated by mTORC1, not mTORC2 activity.

Conclusions:

• Loss of PTEN leads to aberrant neuronal migration with a critical temporal window for intervention.
• Rapamycin can prevent, but not reverse, migration defects in Pten-deficient neurons.
• Findings suggest potential therapeutic strategies for PTEN-mutation associated disorders, emphasizing the need for early intervention.